Literature DB >> 24899663

Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis.

Valeria Rocchi1, Ilaria Puxeddu1, Giuseppe Cataldo1, Isabella Del Corso1, Antonio Tavoni1, Laura Bazzichi1, Stefano Bombardieri1, Paola Migliorini2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24899663     DOI： 10.1093/rheumatology/keu181

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  9 in total

1.  Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.

Authors:  Huifeng Yun; Fenglong Xie; Randall N Beyl; Lang Chen; James D Lewis; Kenneth G Saag; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-10       Impact factor: 4.794

Review 2.  Cutaneous Manifestations of Reactions to Biologics.

Authors:  Iris M Otani; Amy S Levin; Aleena Banerji
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-21       Impact factor: 4.806

Review 3.  Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review.

Authors:  Eun Hye Park; Eun Young Lee; Kichul Shin; Hyoun-Ah Kim
Journal:  Rheumatol Int       Date:  2019-10-09       Impact factor: 2.631

4.  Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center.

Authors:  Rahime Koç; Hafize Emine Sönmez; Mustafa Çakan; Şerife Gül Karadağ; Ayşe Tanatar; Figen Çakmak; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2019-12-21       Impact factor: 2.631

Review 5.  Hypersensitivity Reactions to Biologicals: from Bench to Bedside.

Authors:  Aysegul Akarsu; Ozge Soyer; Bulent Enis Sekerel
Journal:  Curr Treat Options Allergy       Date:  2020-01-18

Review 6.  Hypersensitivity Reactions to Monoclonal Antibodies in Children.

Authors:  Francesca Mori; Francesca Saretta; Annamaria Bianchi; Giuseppe Crisafulli; Silvia Caimmi; Lucia Liotti; Paolo Bottau; Fabrizio Franceschini; Claudia Paglialunga; Giampaolo Ricci; Angelica Santoro; Carlo Caffarelli
Journal:  Medicina (Kaunas)       Date:  2020-05-12       Impact factor: 2.430

Review 7.  Immune-related adverse events of biological immunotherapies used in COVID-19.

Authors:  Daniela Baracaldo-Santamaría; Giovanna María Barros-Arias; Felipe Hernández-Guerrero; Alejandra De-La-Torre; Carlos-Alberto Calderon-Ospina
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

8.  'Toxic erythema' and eosinophilia associated with tocilizumab therapy in a COVID-19 patient.

Authors:  A Sernicola; G Carnicelli; M Di Fraia; C Chello; C Furlan; R Muharremi; G Paolino; T Grieco
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-08       Impact factor: 9.228

9.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.